Free-living use of artificial pancreas for children with type 1 diabetes: systematic review

BACKGRAUND: A closed-loop glucose control system or ‘artificial pancreas’ consists of three components – a Continuous Glucose Monitor (CGM), infusion pumps to deliver hormone(s) and a sophisticated dosing algorithm to control hormone delivery. In the past years, numerou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Klemen Dovc, Gül Yeşiltepe Mutlu, Yury I. Philippov, Dmitry N. Laptev, Evgenia M. Patrakeeva, Lubov O. Chernilova, Alsu G. Zalevskaya, Marina V. Shestakova, Tadej Battelino
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2018
Materias:	diabetes mellitus, type 1 insulin infusion systems pancreas, artificial closed-loop csii cgm sensor augmented pump systematic review randomized control trial children Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/bb3b843fbf3f4df295dbcc4833fa4fb2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb3b843fbf3f4df295dbcc4833fa4fb2
record_format	dspace
spelling	oai:doaj.org-article:bb3b843fbf3f4df295dbcc4833fa4fb22021-11-14T09:00:21ZFree-living use of artificial pancreas for children with type 1 diabetes: systematic review2072-03512072-037810.14341/DM9714https://doaj.org/article/bb3b843fbf3f4df295dbcc4833fa4fb22018-08-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9714https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378BACKGRAUND: A closed-loop glucose control system or ‘artificial pancreas’ consists of three components – a Continuous Glucose Monitor (CGM), infusion pumps to deliver hormone(s) and a sophisticated dosing algorithm to control hormone delivery. In the past years, numerous studies with closed-loop system devices were conducted with gradual shift to out-of-hospital environment and with lengthening study duration. AIMS: To compare efficacy and safety of closed-loop insulin pump use in children with type 1 diabetes mellitus in compare with conventional insulin treatment (continuous subcutaneous insulin infusion (CSII) with our without CGM) based on randomized control trials data (RCT). METHODS: In the systematic review we have include 28 randomized controlled trials results indexed in PubMed, Medline databases published till 15 June 2017. The efficacy on metabolic control in this study evaluated by the proportion of time within target range (preferably 70 to 180 mg/dl if reported) and mean (median) glucose based on sensor measurements, and the safety evaluated by time in hypoglycemia (below 70 mg/dl if reported). RESULTS: Increased time in range in the night period was observed in all RCT. Only 3 RCT showed decrease of the time in range within 24 h evaluation period. In one RCT the significant positive differences have been shown in the time in range for dual hormone closed-loop glucose control system in compare with insulin-only artificial pancreas. Mean glycaemia and glucose variability changes were not in the same manner in different RCT, both in the night only and in 24 h estimation period. Night hypoglycemia duration decreased in most RCT with closed-loop control in compare with CSII, and increased only in 2 RCT. When all-day estimation period the time in hypoglycemia changed not in the same manner in different RCT. Valuable methodology differences of the glycaemic control estimation within observed RCT brought significant complications in the data analysis and made impossible the results quantitative estimation to prepare a metaanalysis. CONCLUSIONS: Much work has been done to develop effective and safe artificial pancreas, but not all RCTs confirmed advantages of closed-loop glucose control in compare with CSII in children and adolescents in real life. More research with prospective randomized control design required to prove benefits of closed-loop glucose control. Further RCTs should have an uniform methodology for glycemic control assessment and long duration that will allow to use cumulative measures in a closed-loop efficacy estimation (HbA1c).Klemen DovcGül Yeşiltepe MutluYury I. PhilippovDmitry N. LaptevEvgenia M. PatrakeevaLubov O. ChernilovaAlsu G. ZalevskayaMarina V. ShestakovaTadej BattelinoEndocrinology Research Centrearticlediabetes mellitus, type 1insulin infusion systemspancreas, artificialclosed-loopcsiicgmsensor augmented pumpsystematic reviewrandomized control trialchildrenNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 3, Pp 206-216 (2018)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus, type 1 insulin infusion systems pancreas, artificial closed-loop csii cgm sensor augmented pump systematic review randomized control trial children Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus, type 1 insulin infusion systems pancreas, artificial closed-loop csii cgm sensor augmented pump systematic review randomized control trial children Nutritional diseases. Deficiency diseases RC620-627 Klemen Dovc Gül Yeşiltepe Mutlu Yury I. Philippov Dmitry N. Laptev Evgenia M. Patrakeeva Lubov O. Chernilova Alsu G. Zalevskaya Marina V. Shestakova Tadej Battelino Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
description	BACKGRAUND: A closed-loop glucose control system or ‘artificial pancreas’ consists of three components – a Continuous Glucose Monitor (CGM), infusion pumps to deliver hormone(s) and a sophisticated dosing algorithm to control hormone delivery. In the past years, numerous studies with closed-loop system devices were conducted with gradual shift to out-of-hospital environment and with lengthening study duration. AIMS: To compare efficacy and safety of closed-loop insulin pump use in children with type 1 diabetes mellitus in compare with conventional insulin treatment (continuous subcutaneous insulin infusion (CSII) with our without CGM) based on randomized control trials data (RCT). METHODS: In the systematic review we have include 28 randomized controlled trials results indexed in PubMed, Medline databases published till 15 June 2017. The efficacy on metabolic control in this study evaluated by the proportion of time within target range (preferably 70 to 180 mg/dl if reported) and mean (median) glucose based on sensor measurements, and the safety evaluated by time in hypoglycemia (below 70 mg/dl if reported). RESULTS: Increased time in range in the night period was observed in all RCT. Only 3 RCT showed decrease of the time in range within 24 h evaluation period. In one RCT the significant positive differences have been shown in the time in range for dual hormone closed-loop glucose control system in compare with insulin-only artificial pancreas. Mean glycaemia and glucose variability changes were not in the same manner in different RCT, both in the night only and in 24 h estimation period. Night hypoglycemia duration decreased in most RCT with closed-loop control in compare with CSII, and increased only in 2 RCT. When all-day estimation period the time in hypoglycemia changed not in the same manner in different RCT. Valuable methodology differences of the glycaemic control estimation within observed RCT brought significant complications in the data analysis and made impossible the results quantitative estimation to prepare a metaanalysis. CONCLUSIONS: Much work has been done to develop effective and safe artificial pancreas, but not all RCTs confirmed advantages of closed-loop glucose control in compare with CSII in children and adolescents in real life. More research with prospective randomized control design required to prove benefits of closed-loop glucose control. Further RCTs should have an uniform methodology for glycemic control assessment and long duration that will allow to use cumulative measures in a closed-loop efficacy estimation (HbA1c).
format	article
author	Klemen Dovc Gül Yeşiltepe Mutlu Yury I. Philippov Dmitry N. Laptev Evgenia M. Patrakeeva Lubov O. Chernilova Alsu G. Zalevskaya Marina V. Shestakova Tadej Battelino
author_facet	Klemen Dovc Gül Yeşiltepe Mutlu Yury I. Philippov Dmitry N. Laptev Evgenia M. Patrakeeva Lubov O. Chernilova Alsu G. Zalevskaya Marina V. Shestakova Tadej Battelino
author_sort	Klemen Dovc
title	Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_short	Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_full	Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_fullStr	Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_full_unstemmed	Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
title_sort	free-living use of artificial pancreas for children with type 1 diabetes: systematic review
publisher	Endocrinology Research Centre
publishDate	2018
url	https://doaj.org/article/bb3b843fbf3f4df295dbcc4833fa4fb2
work_keys_str_mv	AT klemendovc freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview AT gulyesiltepemutlu freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview AT yuryiphilippov freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview AT dmitrynlaptev freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview AT evgeniampatrakeeva freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview AT lubovochernilova freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview AT alsugzalevskaya freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview AT marinavshestakova freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview AT tadejbattelino freelivinguseofartificialpancreasforchildrenwithtype1diabetessystematicreview
_version_	1718429553286709248

Free-living use of artificial pancreas for children with type 1 diabetes: systematic review

Ejemplares similares